Abstract Library

#4502 Molecular analysis of non-functioning PanNETs of the alpha lineage reveals new subtypes and mechanisms of progression

Introduction: Most pancreatic neuroendocrine tumours (PanNETs) are non-functioning. Previously, we demonstrated that small, MEN1-only mutated α-like PanNETs can be distinguished from larger ADM (mutated in ATRX, DAXX and MEN1) PanNETs based on epigenetic profiles. ADM PanNETs have shorter disease-free survival and a higher relapse risk. However, their therapeutic responses vary, underscoring group heterogeneity. ADM PanNETs remain insufficiently characterised, with potential subtype-specific progression drivers with implications for treatment choice and clinical outcome.

Conference:

Presenting Author: Avanthay S

Authors: Avanthay S, Di Domenico A, Kirchner P, Bräutigam K, Chouchane A,

Keywords: pancreas, epigenetics, progression, metastasis, DAXX, ATRX, Pan NET,

#4455 Multicentric ENETS morphological and molecular appraisal of high-grade gastroenteropancreatic neuroendocrine neoplasms (HG-GEP-NEN): Distinguishing NET G3 from NEC

Introduction: HG-GEP-NEN are classified into neuroendocrine tumours grade 3 (NET G3) and neuroendocrine carcinomas (NEC). This distinction is crucial as it affects patient prognosis and treatments but can be challenging.

Conference:

Presenting Author: Tihy M

Authors: Tihy M, Solstad O, Oudijk L, Bräutigam K, Bani M,

Keywords: HG-GEP-NEN, neuroendocrine neoplasm, NEC, NET G3, Classification, Review, criteria, diagnosis, pathology,

#4157 Decoding and targeting of metabolic heterogeneity in pancreatic neuroendocrine tumors (PanNETs): MCT1 and MCT4 in the crosshair for precision therapy

Introduction: Mechanisms driving progression from indolent to aggressive and metastatic disease in PanNET are largely unknown. Recent transcriptome and epigenome analyses suggest a stepwise progression model leading to enhanced proliferation, de-differentiation, and metabolic reprogramming. However, the metabolic landscape at different stages and the therapeutic potential of targeting metabolic proteins remain largely uncharacterized.

Conference:

Presenting Author: Sadowski M

Authors: Bräutigam K, Straub J, Bihi A, Andreasi V, Kirchner P,

Keywords: metabolic heterogeneity, 3D model, precision medicine, metabolic subtype, PanNET, hypoxia, lactate efflux, microvessel density, MCT1/MCT4,

#3725 Progression of pancreatic neuroendocrine tumors (PanNETs) to metastatic disease is associated with MCT4 expression and metabolic heterogeneity

Introduction: Up to 50% of patients with PanNETs present with metastasis at time of diagnosis or relapse after surgery, with highly variable dynamics. The mechanisms driving progression from indolent to metastatic disease are largely unknown. Although having great potential for providing novel therapeutic targets, the metabolic landscape at different tumor stages is only poorly understood. Transcriptome and epigenome analyses of PanNET indicate a potential stepwise progression, which is associated with enhanced proliferation, dedifferentiation and hallmarks of hypoxia.

Conference:

Presenting Author: Sadowski M

Authors: Sadowski M, Bräutigam K, Straub J, Andreasi V, Kirchner P,

Keywords: MCT4, metabolic subtypes, aggressive PanNET, patient-derived tumoroid,

#3631 Are hemicolectomies still indicated in patients with neuroendocrine tumors of the appendix 1-2cm? A retrospective Europe-wide cohort study

Introduction: Awareness of a potential global overtreatment by performing oncological resections for appendiceal neuroendocrine tumors (aNET) 1-2cm is increasing.

Conference:

Presenting Author: Nesti C

Authors: Nesti C, Bräutigam K, Zwahlen M, Perren A,

Keywords: appendix, neuroendocrine tumor, surgery, hemicolectomy, metastasis, survival,